American Thoracic Society (ATS) 2021

Budesonide-albuterol lowers exercise-induced bronchoconstriction in patients with asthma

Elaine Soliven, 20210625000000

Treatment with a fixed-dose combination of budesonide and albuterol (BDA) in a single pressurized metered-dose inhaler (pMDI), also known as PT027, significantly prevents exercise-induced bronchoconstriction (EIB) in adolescents and adults with asthma, according to the TYREE* study presented at ATS 2021.

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

Roshini Claire Anthony, 20210622180001

Children with uncontrolled moderate-to-severe asthma may benefit from treatment with dupilumab which reduced exacerbations and improved lung function, according to results of the phase III VOYAGE study presented at ATS 2021.

COPD tied to excess death risk, even in younger adults

Pearl Toh, 20210615150000

Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

Roshini Claire Anthony, 20210614160001

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

Antibody cocktail cuts hospitalization, death in COVID-19

Pearl Toh, 20210612150000

The REGN-COV2 monoclonal antibody cocktail comprising casirivimab and imdevimab significantly reduces the risk of hospitalization and all-cause death by 71 percent compared with placebo in nonhospitalized patients with COVID-19, according to a large phase III study presented at the ATS 2021 Meeting.

Inhaled treprostinil tied to favourable outcomes in PH-ILD

Audrey Abella, 20210611100000

In post hoc analyses of the phase III INCREASE trial presented at ATS 2021, patients on inhaled treprostinil (iTre) for pulmonary hypertension due to parenchymal lung disease (PH-ILD) were less inclined to have multiple clinical worsening events and more likely to experience clinical improvement vs those on placebo.

Tocilizumab administration for severe COVID-19: Timing matters

Audrey Abella, 20210609100000

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

Pearl Toh, 20210606140100

The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.

Long-term study findings reflect potential of sotatercept for PAH

Audrey Abella, 20210604100000

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.